勃林格殷格翰能倍乐使用说明书

Respimat is a drug developed by Boehringer Ingelheim. It is suitable for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD, referred to as COPD, including chronic bronchitis and emphysema) to relieve symptoms. Next, let’s take a look at the Boehringer Ingelheim instruction manual.

Respimat's generic name: tiotropium bromide/olodaterol, English name: Spiolto® Respimat®, Respimat helps adult patients with chronic obstructive pulmonary disease breathe easier. Founded in 1885, Boehringer Ingelheim is an independent family-owned company headquartered in Germany. It officially entered the Chinese market in 1994 and its Chinese headquarters is located in Shanghai. Core businesses include human pharmaceuticals, animal health, biopharmaceuticals and health innovation divisions. Boehringer Ingelheim's latest financial report for 2019 globally and in China. In 2019, Boehringer Ingelheim achieved global net sales of 19 billion euros and R&D expenditures of nearly 3.5 billion euros.

Slivar Respimat soft mist inhalation uses tiotropium bromide (long-acting anticholinergic drug LAMA) as the agent. The aerosol lasts longer, extending to more than 1.2 seconds. The aerosol injection speed is slow, and the ideal particle content is as high as 70%, ensuring efficient deposition of the drug in the lungs, reaching 51.6%. It provides the possibility to reduce the dose of inhaled drugs while maintaining the same efficacy. Moreover, the new device is easy to use, requiring only three actions: "turn, open, and press", greatly improving patient compliance.

Boehringer Ingelheim announced the results of the OTIVACTO study at the 2018 European Respiratory Society Annual Meeting in Paris, France. The study was an observational European real-world study of 7,443 patients with chronic obstructive pulmonary disease (COPD) treated with Tiotropium/olodaterol. Patients participating in the study experienced improvements in physical function and overall health and expressed high levels of satisfaction with the inhaler device and overall treatment. Improvements were observed across patients with varying disease severity. More than two-thirds (67.8%) of patients achieved treatment success. Improvement of disease was observed in all GOLD patient groups, with the most successful treatment occurring in patients with significant symptoms: 79.7% of patients classified as group D achieved treatment success, while 70.9% of patients classified as group B achieved treatment success.

Recommended related articles:

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.